Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC9733-0001 · 1 trial · 2 indications
Measured as number of events
Measured as number of episodes
| Arm | Type | Description |
|---|---|---|
| NNC9733-0001 | EXPERIMENTAL | Participants will be administered a single dose of NNC9733-0001 in a dose escalated manner. |
| Placebo | EXPERIMENTAL | Participants will be administered a single dose of matching NNC9733-0001 placebo in a dose escalated manner. |
| Name | Type | Description |
|---|---|---|
| NNC9733-0001 | DRUG | Administered a single dose of NNC9733-0001. |
| Placebo | DRUG | Administered a single dose of matching NNC9733-0001 placebo. |
Inclusion Criteria: All participants * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine eligibility for the study. * Male, or female of nonchildbearing potential ...
Top 16 of 30 competitors
NNC9733-0001 is an investigational small molecule medicine being developed by Novo Nordisk for the treatment of type 2 diabetes. It is in Phase 1 clinical development and has not been approved for any use. It is being studied in healthy volunteers and in participants with type 2 diabetes.
NNC9733-0001 is being studied as a potential treatment for type 2 diabetes. It is an investigational therapy in Phase 1 testing, so it is not yet available as a prescribed treatment. Research so far includes healthy volunteers alongside participants with type 2 diabetes.
NNC9733-0001 is being developed by Novo Nordisk A/S, the Danish pharmaceutical company whose shares trade under the ticker NVO. Novo Nordisk is the sponsor of the clinical program for this small molecule candidate in type 2 diabetes.
NNC9733-0001 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulator. The program currently has one active trial, with no completed trials reported to date.
NNC9733-0001 is being evaluated in a single Phase 1 trial, NCT07270731, titled a research study of NNC9733-0001 in healthy participants and participants with type 2 diabetes. The trial is recruiting, is randomized, double blind, and controlled, and is expected to enroll about 60 participants in Germany.